Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2015

01-10-2015 | Research Article

Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis

Authors: Cornelius Kwang-Lee Chieng, Yee-How Say

Published in: Tumor Biology | Issue 10/2015

Login to get access

Abstract

As the cellular prion protein (PrPC) has been implicated in carcinogenesis, we aimed to investigate the effects of cancer cell-specific PrPC overexpression from the invasion, metastasis, and apoptosis aspects, by performing cell motility assays, cell proliferation assays under anchorage-dependent and anchorage-independent conditions, and apoptosis evasion when subjected to multiple anti-cancer drugs. Overexpression of PrPC in LS 174T was achieved by stable transfection. PrPC overexpression was shown to increase cell proliferation in anchorage-dependent and anchorage-independent manners, as shown by more viable cells in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, more colonies formed in soft agar assay and increased resistance to anoikis in poly-2-hydroxyethyl methacrylate-coated surface. PrPC overexpression also increased cell motility and invasiveness of LS 174T. Cell adhesion to extracellular matrix using collagen- and fibronectin-coated surfaces revealed increased cell attachment in LS 174T cells overexpressing PrPC. Analysis of apoptotic and necrotic cells by propidium iodide/annexin V-fluorescein isothiocyanate microscopy and 7-amino-actinomycin D/annexin V-phycoerythrin flow cytometry revealed that PrPC overexpression attenuated doxorubicin-induced apoptosis. Human apoptosis antibody array with 35 apoptosis-related proteins revealed that three inhibitor of apoptosis proteins (IAPs)—survivin, X-linked inhibitor of apoptosis protein (XIAP), and cellular inhibitor of apoptosis protein-1 (cIAP-1)—were upregulated in LS 174T cells overexpressing PrPC in doxorubicin-induced apoptosis. In conclusion, the overexpression of PrPC could enhance the invasiveness and survival of LS 174T colorectal cancer cells, indicating that PrPC plays a role in colorectal cancer biology.
Appendix
Available only for authorised users
Literature
1.
2.
3.
Martin-Lannerée S, Hirsch TZ, Hernandez-Rapp J, Halliez S, Vilotte JL, Launay JM, et al. PrP(C) from stem cells to cancer. Front Cell Dev Biol. 2014;2:55.PubMedPubMedCentral
4.
Roucou X, LeBlanc AC. Cellular prion protein neuroprotective function: implications in prion diseases. J Mol Med. 2005;83:3–11.CrossRefPubMed
5.
Mehrpour M, Codogno P. Prion protein: from physiology to cancer biology. Cancer Lett. 2010;290:1–23.CrossRefPubMed
6.
Yang X, Zhang Y, Zhang L, He T, Zhang J, Li C. Prion protein and cancers. Acta Biochim Biophys Sin (Shanghai). 2014;46:431–40.CrossRef
7.
Diarra-Mehrpour M, Arrabal S, Jalil A, Pinson X, Gaudin C, Pietu G, et al. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death. Cancer Res. 2004;64:719–27.CrossRefPubMed
8.
Meslin F, Hamai A, Gao P, Jalil A, Cahuzac N, Chouaib S, et al. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Cancer Res. 2007;67:10910–9.CrossRefPubMed
9.
Li QQ, Cao XX, Xu JD, Chen Q, Wang WJ, Tang F, et al. The role of P-glycoprotein/cellular prion protein interaction in multidrug-resistant breast cancer cells treated with paclitaxel. Cell Mol Life Sci. 2009;66:504–15.CrossRefPubMed
10.
Pan Y, Zhao L, Liang J, Liu J, Shi Y, Liu N, et al. Cellular prion protein promotes invasion and metastasis of gastric cancer. FASEB J. 2006;20:1886–8.CrossRefPubMed
11.
Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, et al. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J. 2007;21:2247–56.CrossRefPubMed
12.
Yap YH, Say YH. Resistance against apoptosis by the cellular prion protein is dependent on its glycosylation status in oral HSC-2 and colon LS 174T cancer cells. Cancer Lett. 2011;306:111–9.CrossRefPubMed
13.
Yap YH, Say YH. Resistance against tumor necrosis factor α apoptosis by the cellular prion protein is cell-specific for oral, colon and kidney cancer cell lines. Cell Biol Int. 2012;36:273–7.CrossRefPubMed
14.
Roucou X, Giannopoulos PN, Zhang Y, Jodoin J, Goodyer CG, LeBlanc A. Cellular prion protein inhibits proapoptotic Bax conformational change in human neurons and in breast carcinoma MCF-7 cells. Cell Death Differ. 2005;12:783–95.CrossRefPubMed
15.
Carethers JM, Pham TT. Mutations of transforming growth factor beta 1 type II receptor, BAX, and insulin-like growth factor II receptor genes in microsatellite unstable cell lines. In Vivo. 2000;14:13–20.PubMed
16.
17.
Parmar N, Wetton N, Alvarado S, Kennedy S. Profiling of human normal and cancer cell lines using phenotype microarray analysis (613.5). FASEB J. 2014;28(1 Supplement):613–5.
18.
Geback T, Schulz MM, Koumoutsakos P, Detmar M. TScratch: a novel and simple software tool for automated analysis of monolayer wound healing assays. Biotechniques. 2009;46:265–74.PubMed
19.
Li C, Yu S, Nakamura F, Yin S, Xu J, Petrolla AA, et al. Binding of pro-prion to filamin A disrupts cytoskeleton and correlates with poor prognosis in pancreatic cancer. J Clin Invest. 2009;119:2725–36.CrossRefPubMedPubMedCentral
20.
Li QQ, Sun YP, Ruan CP, Xu XY, Ge JH, He J, et al. Cellular prion protein promotes glucose uptake through the Fyn-HIF-2α-Glut1 pathway to support colorectal cancer cell survival. Cancer Sci. 2011;102:400–6.CrossRefPubMed
21.
Liang J, Wang J, Luo G, Pan Y, Wang X, Guo C, et al. Function of PrPC (1-OPRD) in biological activities of gastric cancer cell lines. J Cell Mol Med. 2009;13:4453–64.CrossRefPubMedPubMedCentral
22.
23.
Li C, Yu S, Nakamura F, Pentikäinen OT, Singh N, Yin S, et al. Pro-prion binds filamin A, facilitating its interaction with integrin beta1, and contributes to melanomagenesis. J Biol Chem. 2010;285:30328–39.CrossRefPubMedPubMedCentral
24.
Wang Q, Qian J, Wang F, Ma Z. Cellular prion protein accelerates colorectal cancer metastasis via the Fyn-SP1-SATB1 axis. Oncol Rep. 2012;28:2029–34.PubMed
25.
Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996;84:359–69.CrossRefPubMed
26.
27.
Zhao Y, You H, Liu F, An H, Shi Y, Yu Q, et al. Differentially expressed gene profiles between multidrug resistant gastric adenocarcinoma cells and their parental cells. Cancer Lett. 2002;185:211–8.CrossRefPubMed
28.
Yu G, Jiang L, Xu Y, Guo H, Liu H, Zhang Y, et al. Silencing prion protein in MDA-MB-435 breast cancer cells leads to pleiotropic cellular responses to cytotoxic stimuli. PLoS One. 2012;7, e48146.CrossRefPubMedPubMedCentral
29.
Reed JC. Bcl-2 family proteins: regulator of apoptosis and chemoresistance in haematologic malignancies. Semin Hematol. 1997;34:9–19.PubMed
30.
Atlante A, Calissano P, Bobba A, Azzariti A, Marra E, Passarella S. Cytochrome c is released from mitochondria in a reactive oxygen species (ROS)-dependent fashion and can operate as a ROS scavenger and as a respiratory substrate in cerebellar neurons undergoing excitotoxic death. J Biol Chem. 2000;275:37159–66.CrossRefPubMed
31.
Hüttemann M, Pecina P, Rainbolt M, Sanderson TH, Kagan VE, Samavati L, et al. The multiple functions of cytochrome c and their regulation in life and death decisions of the mammalian cell: from respiration to apoptosis. Mitochondrion. 2011;11:369–81.CrossRefPubMedPubMedCentral
32.
Brown DR. Neurodegeneration and oxidative stress: prion disease results from loss of antioxidant defence. Folia Neuropathol. 2005;43(4):229–43.PubMed
33.
34.
Kim PJ, Plescia J, Clevers H, Fearon ER, Altieri DC. Survivin and molecular pathogenesis of colorectal cancer. Lancet. 2003;362:205–9.CrossRefPubMed
35.
Hernandez JM, Farma JM, Coppola D, Hakam A, Fulp WJ, Chen DT, et al. Expression of the antiapoptotic protein survivin in colon cancer. Clin Colorectal Cancer. 2011;10:188–93.CrossRefPubMed
36.
Hehlgans S, Petraki C, Reichert S, Cordes N, Rödel C, Rödel F. Double targeting of surviving and XIAP radiosensitizes 3D grown human colorectal tumor cells and decreases migration. Radiother Oncol. 2013;108:32–9.CrossRefPubMed
37.
Wong RSY. Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res. 2011;30:1–14.CrossRef
38.
O’Brien MA, Kirby R. Apoptosis: a review of pro-apoptotic and anti apoptotic pathway and dysregulation in diseases. J Vet Emerg Crit Care. 2008;18:572–85.CrossRef
39.
40.
Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilisation in cell death. Physiol Rev. 2007;87:99–163.CrossRefPubMed
41.
Dohi T, Okada K, Xia F, Wilford CE, Samuel T, Welsh K, et al. An IAP-IAP complex inhibits apoptosis. J Biol Chem. 2004;279:34087–90.CrossRefPubMed
42.
Gewirtz DA, Sundaram S, Magnet KJ. Influence of topoisomerase II inhibitors and ionizing radiation on growth arrest and cell death pathways in the breast tumor cell. Cell Biochem Biophys. 2000;33:19–31.CrossRefPubMed
43.
Gartel AL, Tyner AL. The role of cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther. 2002;1:639–49.PubMed
44.
Weiss E, Ramljak S, Asif AR, Ciesielczyk B, Schmitz M, Gawinecka J, et al. Cellular prion protein overexpression disturbs cellular homeostasis in SH-SY5Y neuroblastoma cells but does not alter p53 expression: a proteomic study. Neuroscience. 2010;169:1640–50.CrossRefPubMed
Metadata
Title
Cellular prion protein contributes to LS 174T colon cancer cell carcinogenesis by increasing invasiveness and resistance against doxorubicin-induced apoptosis
Authors
Cornelius Kwang-Lee Chieng
Yee-How Say
Publication date
01-10-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3530-z

Other articles of this Issue 10/2015

Tumor Biology 10/2015 Go to the issue

Research Article

Serum miR-182 and miR-331-3p as diagnostic and prognostic markers in patients with hepatocellular carcinoma

Review

Gene mutations in gastric cancer: a review of recent next-generation sequencing studies

Research Article

Homocysteine: new tumor marker in pleural fluid

Research Article

High peritumoral Bmi-1 expression is an independent prognosticator of poor prognosis in renal cell carcinoma

Research Article

Expression of toll-like receptors in HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma—an in vivo and in vitro study

Research Article

Regulation of AURKC expression by CpG island methylation in human cancer cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits